When was NeuMoDx founded?

NeuMoDx was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is NeuMoDx located?

NeuMoDx is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan.

How many employees does NeuMoDx have?

As of Jul 31, 2026, the latest employee count at NeuMoDx is 20.

Is NeuMoDx a funded company?

NeuMoDx is a funded company, having raised a total of $66M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 09, 2012.

How much is NeuMoDx worth?

The last known valuation of NeuMoDx was $***** as of Sep 17, 2020.

When was the latest funding round of NeuMoDx?

NeuMoDx's latest funding was a $***** Series B round on Apr 27, 2018, with participation from 0 investor. Its primary sector is Clinical Genomics. In United States, the Clinical Genomics sector has seen $457M in funding in 2026 to date.

Where does NeuMoDx rank among its competitors?

NeuMoDx ranks 2nd amongst 109 active competitors, of which 21 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Kryptos Biotechnologies, which secured $10M in Mar, 2024.

Who are the top competitors of NeuMoDx?

NeuMoDx's top competitors include Biocartis, GenMark Diagnostics and QuantuMDx Group. Among them, Kryptos Biotechnologies secured the most recent funding round in March, 2024.

NeuMoDx - 2026 Company Profile, Team, Funding & Competitors

Q: Is NeuMoDx an acquired company?

NeuMoDx got acquired by Qiagen on Sep 17, 2020.

Company Details

NeuMoDx is developing a patent-pending platform for low-cost molecular testing. It integrates magnetic particle affinity capture and real-time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. Its lead product NeuMoDx 500 is a molecular IVD system that is a fully automated, random access platform capable of performing RNA and DNA-based assays.

Website: neumodx.com
Social
Email ID: *****@neumodx.com
Registered Address: Ann Arbor, Michigan

Key Metrics

Founded Year

2012

Location

Ann Arbor, United States

Stage

Acquired

Total Funding

$66M in 5 rounds

Latest Funding Round

Series B, Apr 27, 2018, $*****

Last Known Valuation

$***** as on Sep 17, 2020

Investors

Arboretum Ventures & 4 more

Ranked

2^nd among 109 active competitors

Employee Count

20 as on Jul 31, 2026

Similar Companies

GenMark Diagnostics & 128 more

Exit Details

Acquired by Qiagen (Sep 17, 2020)

View NeuMoDx's full profile

NeuMoDx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neumodx Molecular, Inc CIN: 274160917 , United States, Active	Dec 31, 1999	-	125 (As on Dec 31, 2019)	-

NeuMoDx got acquired by Qiagen on Sep 17, 2020 at an acquisition amount of $*****.

Click here to take a look at NeuMoDx's acquisition in detail

NeuMoDx has raised a total funding of $66M over 5 rounds. Its first funding round was on Apr 09, 2012. NeuMoDx has 5 institutional investors.

Here is the list of recent funding rounds of NeuMoDx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 27, 2018	2630681	Series B	7852217	9074688	5943352	5604194
Mar 05, 2018	1017047	Conventional Debt	9374321	5503947	9944187	8738244
Apr 29, 2016	5674942	Series B	7099399	5930530	4434028	6964054

Access funding benchmarks and valuations. Sign up today!

View details of NeuMoDx's funding rounds and investors

NeuMoDx's employee count trend

NeuMoDx has 20 employees as of Jul 26. Here is NeuMoDx's employee count trend over the years:

Uncover NeuMoDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuMoDx include Biocartis, GenMark Diagnostics and QuantuMDx Group. Here is the list of Top 10 competitors of NeuMoDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biocartis 2007, Mechelen (Belgium), Public	Manufacturer of automated molecular diagnostic systems for oncology biomarker testing	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	58/100
2nd	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Baird Capital, Arboretum Ventures & 3 others	52/100
3rd	GenMark Diagnostics 1993, San Diego (United States), Acquired	Provider of instruments and test panels for multiplexed molecular diagnostics	$8.56M	SLR Investment Corp, VIDANT Capital	49/100
4th	QuantuMDx Group 2008, Newcastle Upon Tyne (United Kingdom), Series D	Manufacturer of molecular diagnostic platforms and assays for infectious diseases	$57.3M	Adjuvo, WG Partners & 3 others	49/100
5th	Quantalife 2008, Pleasanton (United States), Acquired	Life science research and clinical diagnostics solutions provider, powering possibilities	$28.7M	Paladin Capital, Vital Venture Capital & 3 others	48/100
6th	Co-Dx 2013, Salt Lake City (United States), Public	Provider of genomics-based information and solutions for transplant patients	$1.1M	NIH, SALSS	48/100
7th	Bigtec Labs 2000, Bengaluru (India), Funding Raised	Developer of point-of-care solutions for nucleic acid amplification tests	-	C-CAMP, Grand Challenges Canada & 3 others	47/100
8th	Molecular Designs 2019, Birmingham (United States), Funding Raised	Developer of molecular diagnostic kits for the detection of a wide range of diseases	-	Excellere Partners, Excellere	46/100
9th	Kryptos Biotechnologies 2017, Hayward (United States), Series A	Biotechnology company illuminating complex diseases with innovative diagnostic and life science solutions	$12.7M	Coolidge Corner Investment, FuturePlay & 6 others	45/100
10th	miniPCR 2013, Cambridge (United States), Funding Raised	Developer of easy-to-use PCR and electrophoresis instruments	-	MassChallenge	45/100